Cue Biopharma, Inc.
CUE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.04 | 0.09 | 0.07 |
| FCF Yield | -5.28% | -12.30% | -11.16% | -19.40% |
| EV / EBITDA | -5.43 | -5.48 | -7.21 | -2.09 |
| Quality | ||||
| ROIC | -33.23% | -89.74% | -36.52% | -23.34% |
| Gross Margin | 96.61% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.21 | 0.40 | 0.67 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.95% | 66.73% | 164.47% | 95.39% |
| Free Cash Flow Growth | 58.64% | 7.84% | -19.98% | 24.74% |
| Safety | ||||
| Net Debt / EBITDA | 2.38 | 0.53 | 1.45 | 3.02 |
| Interest Coverage | -191.89 | -96.09 | -62.96 | -46.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,248.09 | 0.00 | 53.97 | 85.04 |